Fig. 2From: The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study a Levels of IL-1ß at baseline and after 12 weeks of treatment; b Percent change of IL-1ß {Δ% = [(value after treatment−baseline value)/baseline value × 100]}Back to article page